Article
Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma – a case report
2024-01-02
Abstract excerpt
<title>Abstract</title> <p>The use of Bruton's tyrosine kinase inhibitors (BTKi) is rapidly increasing for patients with mantle cell lymphoma (MCL). Side effects reported so far are usually manageable and self-determining after dose-reduction or termination of the drug. However, here we present a new aspect of BTKi’s that needs to be taken into consideration as we report two cases of life-threatening aplastic ane...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e45a179a-9965-5dd7-9dd6-c14fa00475f5
- DOI
- 10.21203/rs.3.rs-3795875/v1
